kynurenine has been researched along with Triple Negative Breast Neoplasms in 6 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of LY3381916 monotherapy and in combination with a programmed death-ligand 1 (PD-L1) inhibitor (LY3300054) in patients with advanced solid tumors." | 3.01 | A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. ( Bendell, J; Benhadji, KA; Doman, TN; Galvao, VR; Gandhi, L; Geeganage, S; Jalal, S; Kotecki, N; O'Neil, BH; Prenen, H; Rottey, S; Saha, A; Suriyapperuma, S; Szpurka, AM; Vuagnat, P; Wallin, J; Xia, M; Xu, X, 2021) |
| " For some parameters, U-shaped or inverted U-shaped dose-response curves are shown." | 1.91 | Breast cancer progression and kynurenine pathway enzymes are induced by hexachlorobenzene exposure in a Her2-positive model. ( Candolfi, M; Chiappini, FA; Miret, NV; Monczor, F; Nicola Candia, AJ; Pontillo, CA; Randi, AS; Zappia, CD; Zárate, LV, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zárate, LV | 1 |
| Miret, NV | 1 |
| Nicola Candia, AJ | 1 |
| Zappia, CD | 1 |
| Pontillo, CA | 1 |
| Chiappini, FA | 1 |
| Monczor, F | 1 |
| Candolfi, M | 1 |
| Randi, AS | 1 |
| Diedrich, JD | 1 |
| Gonzalez-Pons, R | 1 |
| Medeiros, HCD | 1 |
| Ensink, E | 1 |
| Liby, KT | 1 |
| Wellberg, EA | 1 |
| Lunt, SY | 1 |
| Bernard, JJ | 1 |
| Sordillo, LA | 1 |
| Sordillo, PP | 1 |
| Kotecki, N | 1 |
| Vuagnat, P | 1 |
| O'Neil, BH | 1 |
| Jalal, S | 1 |
| Rottey, S | 1 |
| Prenen, H | 1 |
| Benhadji, KA | 1 |
| Xia, M | 1 |
| Szpurka, AM | 1 |
| Saha, A | 1 |
| Wallin, J | 1 |
| Suriyapperuma, S | 1 |
| Galvao, VR | 1 |
| Geeganage, S | 1 |
| Doman, TN | 1 |
| Gandhi, L | 1 |
| Xu, X | 1 |
| Bendell, J | 1 |
| Rogers, TJ | 2 |
| Christenson, JL | 1 |
| Greene, LI | 2 |
| O'Neill, KI | 1 |
| Williams, MM | 1 |
| Gordon, MA | 2 |
| Nemkov, T | 1 |
| D'Alessandro, A | 2 |
| Degala, GD | 1 |
| Shin, J | 1 |
| Tan, AC | 1 |
| Cittelly, DM | 1 |
| Lambert, JR | 1 |
| Richer, JK | 2 |
| D'Amato, NC | 1 |
| Cochrane, DR | 1 |
| Spoelstra, NS | 1 |
| Nemkov, TG | 1 |
| Hansen, KC | 1 |
1 review available for kynurenine and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Suppression of Kynurenine 3-Monooxygenase as a Treatment for Triple-negative Breast Carcinoma.
Topics: Brain; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Kynurenine 3-Monooxygenase; Treatme | 2023 |
1 trial available for kynurenine and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cel | 2021 |
4 other studies available for kynurenine and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Breast cancer progression and kynurenine pathway enzymes are induced by hexachlorobenzene exposure in a Her2-positive model.
Topics: Cell Line, Tumor; Dioxygenases; Estrogen Receptor beta; Female; Hexachlorobenzene; Humans; Kynurenin | 2023 |
Adipocyte-derived kynurenine stimulates malignant transformation of mammary epithelial cells through the aryl hydrocarbon receptor.
Topics: Adipocytes; Epithelial Cells; Hormones; Humans; Kynurenine; Ligands; Receptors, Aryl Hydrocarbon; Tr | 2023 |
Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression.
Topics: Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; | 2019 |
A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
Topics: Animals; Anoikis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, N | 2015 |